
Opinion|Videos|July 22, 2024
Real-World Data for Risdiplam in Adult Patients with Spinal Muscular Atrophy
Panelists examine the available real-world data (RWD) on the use of risdiplam in adult patients with spinal muscular atrophy (SMA) from various studies conducted worldwide, discussing its potential efficacy and safety as a treatment option for adult SMA patients.
Advertisement
Episodes in this series

- Discuss real-world evidence for risdiplam in adult patients.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Understanding VTX3232’s Effects on Patients with Early-Stage Parkinson Disease
2
Ocrelizumab’s Encouraging Treatment Effects Across Conception Delivery and Breastfeeding
3
Key Diagnostic Pearls for NMOSD Recognition and Testing: Elena Grebenciucova, MD
4
2025 CNS Annual Meeting: Top Expert Interviews and Key Takeaways
5









































